PROK
ProKidney Corp. Class A
stockNASDAQ
prokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney's lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy. react™ has received regenerative medicine advanced therapy (rmat) designation, as well as fda and ema guidance, supporting its ongoing phase 3 clinical program, which launched in january 2022. for more information, visit www.prokidney.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.74 | 2026-10-09 | -23.85% | 3.621 |
| 1M | 1.80 | 2026-09-17 | -26.39% | 0.629 |
| 3M | 1.62 | 2026-07-17 | -18.21% | 1.030 |
| 6M | 2.18 | 2026-04-17 | -39.22% | 1.145 |
| 1Y | 2.97 | 2025-10-17 | -55.39% | 1.799 |
| 2Y | 1.98 | 2024-10-17 | -33.08% | — |
| 5Y | 8.75 | 2022-07-13 | -84.86% | 1.752 |
ProKidney Corp. Class A (NASDAQ:PROK) stock price today is $1.33, and today's volume is 1,669,720. PROK is down 8.935% today. The 30 day average volume is 1.60M. PROK market cap is $276.83M with 208.93M shares outstanding.